Clinical development of neridronate: potential for new applications

References

• GattiDViapianaOIdolazziLFracassiEAdamiSNeridronic acid for the treatment of bone metabolic diseasesExpert Opin Drug Metab Toxicol20095101305131119761412
   PubMed Web of Science ®Google Scholar
• EbetinoFHHoganAMSunSThe relationship between the chemistry and biological activity of the bisphosphonatesBone2011491203321497677
   PubMed Web of Science ®Google Scholar
• EbetinoFHBaylessAVAmburgeyJIbbotsonKJDansereauSEbrahimpourAElucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activityPhosphorus Sulfur Silicon Relat Elem19961091–4217220
   Web of Science ®Google Scholar
• AminDCornellSAGustafsonSKBisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesisJ Lipid Res199233165716631464749
   PubMed Web of Science ®Google Scholar
• GrahamDYMalatyHMGoodgameRPrimary amino-bisphosphonates: a new class of gastrotoxic drugs-comparison of alendronate and aspirinAm J Gastroenterol1997928132213259260798
   PubMed Web of Science ®Google Scholar
• LinJHBisphosphonates: a review of their pharmacokinetic propertiesBone199618275858833200
   PubMed Web of Science ®Google Scholar
• DevogelaerJPMalghemJMaldagueBNagant de DeuxchaisnesCRadiological manifestations of bisphosphonate treatment with APD in a children suffering from osteogenesis imperfectaSkeletal Radiol19871653603633629280
   PubMed Web of Science ®Google Scholar
• RauchFGlorieuxFHOsteogenesis imperfectaLancet200436394181377138515110498
   PubMed Web of Science ®Google Scholar
• GlorieuxFHBishopNJPlotkinHChabotGLanoueGTraversRCyclic administration of pamidronate in children with severe osteogenesis imperfectaN Engl J Med1998339149479529753709
   PubMed Web of Science ®Google Scholar
• LandCRauchFMunnsCFSahebjamSGlorieuxFHVertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatmentBone200639490190616730480
   PubMed Web of Science ®Google Scholar
• PlotkinHRauchFBishopNJPamidronate treatment of severe osteogenesis imperfecta in children under 3 years of ageJ Clin Endocrinol Metab20008551846185010843163
   PubMed Web of Science ®Google Scholar
• GattiDAntoniazziFPrizziRIntravenous neridronate in children with osteogenesis imperfecta: a randomized controlled studyJ Bone Miner Res200520575876315824848
   PubMed Web of Science ®Google Scholar
• AntoniazziFZamboniGLauriolaSDonadiLAdamiSTatòLEarly bisphosphonate treatment in infants with severe osteogenesis imperfectaJ Pediatr2006149217417916887429
   PubMed Web of Science ®Google Scholar
• AdamiSGattiDColapietroFIntravenous neridronate in adults with osteogenesis imperfectaJ Bone Miner Res200318112623012510813
   PubMed Web of Science ®Google Scholar
• SemlerOBeccardRPalmisanoDReshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfectaHorm Res Paediatr201176532132721952409
   PubMed Web of Science ®Google Scholar
• MariniJCBordenickSHeavnerGThe growth hormone and somatomedin axis in short children with osteogenesis imperfectaJ Clin Endocrinol Metab19937612512568421094
   PubMed Web of Science ®Google Scholar
• AntoniazziFBertoldoFMottesMGrowth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesisJ Pediatr199612934324398804334
   PubMed Web of Science ®Google Scholar
• MariniJCHopkinsEGlorieuxFHPositive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagenJ Bone Miner Res200318223724312568401
   PubMed Web of Science ®Google Scholar
• AntoniazziFMontiEVenturiGGH in combination with bisphosphonate treatment in osteogenesis imperfectaEur J Endocrinol2010163347948720592128
   PubMed Web of Science ®Google Scholar
• GuttaRLouisPJBisphosphonates and osteonecrosis of the jaws: science and rationaleOral Surg Oral Med Oral Pathol Oral Radiol Endod2007104218619317448709
   PubMed Web of Science ®Google Scholar
• MainesEMontiEDoroFMorandiGCavarzerePAntoniazziFChildren and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jawJ Bone Miner Metab201230443443822065238
   PubMed Web of Science ®Google Scholar
• FalchettiAMariniFMasiLAmedeiABrandiMLGenetic aspects of the Paget’s disease of bone: concerns on the introduction of DNA-based tests in the clinical practice. Advantages and disadvantages of its applicationEur J Clin Invest201040765566720658751
   PubMed Web of Science ®Google Scholar
• AdamiSBevilacquaMBrogginiMShort-term intravenous therapy with neridronate in Paget’s diseaseClin Exp Rheum20022015558
   PubMed Web of Science ®Google Scholar
• WalshJPWardLCStewartGOA randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of boneBone200434474775415050907
   PubMed Web of Science ®Google Scholar
• ReidIRMillerPLylesKComparison of a single infusion of zoledronic acid with risedronate for Paget’s diseaseN Engl J Med2005353989890816135834
   PubMed Web of Science ®Google Scholar
• HoskingDLylesKBrownJPLong-term control of bone turnover in Paget’s disease with zoledronic acid and risedronateJ Bone Miner Res200722114214817032148
   PubMed Web of Science ®Google Scholar
• MerlottiDRendinaDGennariLComparison of different intravenous bisphosphonate regimens for Paget’s disease of boneJ Bone Miner Res200722101510151717605632
   PubMed Web of Science ®Google Scholar
• MerlottiDRendinaDGennariLComparison of Intravenous and Intramuscular neridronate regimens for the treatment of Paget disease of boneJ Bone Miner Res201126351251820814970
   PubMed Web of Science ®Google Scholar
• BragaVGattiDColapietroFIntravenous intermittent neridronate in the treatment of postmenopausal osteoporosisBone200333334234513678775
   PubMed Web of Science ®Google Scholar
• CascellaTMusellaTOrioFEffects of neridronate treatment in elderly women with osteoporosisJ Endocrinol Invest200528320220815952402
   PubMed Web of Science ®Google Scholar
• AdamiSGattiDBertoldoFIntramuscular neridronate in postmenopausal women with low bone mineral densityCalcif Tissue Int200883530130718946626
   PubMed Web of Science ®Google Scholar
• GattiDViapianaOAdamiSIdolazziLFracassiERossiniMBisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostinBone201250373974222178539
   PubMed Web of Science ®Google Scholar
• GattiDViapianaOIdolazziLFracassiERossiniMThe waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1J Clin Endocrinol Metab20119651555155921367927
   PubMed Web of Science ®Google Scholar
• GattiDViapianaOFracassiESclerostin and DKK1 in postmenopausal osteoporosis treated with denosumabJ Bone Miner Res201227112259226322692843
   PubMed Web of Science ®Google Scholar
• De NijsRNGlucocorticoid-induced osteoporosis: a review on pathophysiology and treatment optionsMinerva Med2008991234318299694
   PubMedGoogle Scholar
• CanalisEBilezikianJPAngeliAGiustinaAPerspectives on glucocorticoid induced osteoporosisBone200634459359815050888
   PubMed Web of Science ®Google Scholar
• BenucciMSaviolaGBaiardiPEffects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoidsClin Exp Rheumatol200927456757319772786
   PubMed Web of Science ®Google Scholar
• DiamantiANotoCBassoMSPapadatouBBracciFCastroMEfficacy and safety of intravenous neridronate in pediatric bone loss associated to Crohn’s disease: a case reportClin Exp Rheumatol200927116519327248
   PubMed Web of Science ®Google Scholar
• Tran deQHDuongSBertiniPFinlaysonRJTreatment of complex regional pain syndrome: a review of the evidenceCan J Anaesth201057214916620054678
   PubMed Web of Science ®Google Scholar
• AdamiSFossaluzzaVGattiDBisphosphonate therapy of reflex sympathetic dystrophy syndromeAnn Rheum Dis1997562012049135227
   PubMed Web of Science ®Google Scholar
• VarennaMZucchiFGhiringhelliDIntravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled studyJ Rheumatol2000271477148310852274
   PubMed Web of Science ®Google Scholar
• RobinsonJNSandomJChapmanPTEfficacy of pamidronatein complex regional pain syndrome type IPain Med2004527628015367305
   PubMed Web of Science ®Google Scholar
• ManicourtDHBrasseurJPBoutsenYRole of alendronate in therapy for post-traumatic complex regional pain syndrome type I of the lower extremityArthritis Rheum2004503690369715529370
   PubMed Web of Science ®Google Scholar
• BrunnerFSchmidAKisslingRBiphosphonates for the therapy of complex regional pain syndrome I – systematic reviewEur J Pain200913172118440845
   PubMed Web of Science ®Google Scholar
• VarennaMAdamiSRossiniMTreatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled studyRheumatology201352353454223204550
   PubMed Web of Science ®Google Scholar
• HaidarRMusallamKMTaherATBone disease and skeletal complications in patients with β thalassemia majorBone201148342543221035575
   PubMed Web of Science ®Google Scholar
• LascoAMorabitoNGaudioABuemiMWasniewskaMFrisinaNEffects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia majorOsteoporos Int200112757057511527055
   PubMed Web of Science ®Google Scholar
• KarimiMGhiamAFHashemiAAlinejadSSoweidMKashefSBone mineral density in beta-thalassemia major and intermediaIndian Pediatr2007441293217277428
   PubMed Web of Science ®Google Scholar
• BaldiniMFortiSMarconAEndocrine and bone disease in appropriately treated adult patients with beta-thalassemia majorAnn Hematol201089121207121320582415
   PubMed Web of Science ®Google Scholar
• ForniGLPerrottaSGiustiANeridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label studyBr J Haematol2012158227428222571408
   PubMed Web of Science ®Google Scholar
• RossiniMViapianaOKalpakciogluBLong-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidismCalcif Tissue Int2011891212821567168
   PubMed Web of Science ®Google Scholar
• GrazianiFCeiSGuerreroALack of short-term adjunctive effect of systemic neridronate in non-surgical periodontal therapy of advanced generalized chronic periodontitis: an open label-randomized clinical trialJ Clin Periodontol200936541942719419443
   PubMed Web of Science ®Google Scholar
• Mackiewicz-WysockaMPankowskaMWysockiPJProgress in the treatment of bone metastases in cancer patientsExpert Opin Investig Drugs2012216785795
   PubMed Web of Science ®Google Scholar
• MhaskarRRedzepovicJWheatleyKBisphosphonates in multiple myeloma: a network meta-analysisCochrane Database Syst Rev20125CD00318822592688
   PubMed Web of Science ®Google Scholar
• PittariGCostiDRaballoMIntravenous neridronate for skeletal damage treatment in patients with multiple myelomaActa Biomed200677818417172186
   PubMedGoogle Scholar
• O’RourkeNPMcCloskeyEVRosiniSTreatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)Br J Cancer1994699149178180023
   PubMed Web of Science ®Google Scholar
• ChebbiIMigianu-GriffoniESainte-CatherineOLecouveyMSeksekOIn vitro assessment of liposomal neridronate on MDA-MB-231 human breast cancer cellsInt J Pharm20103831–211612219748562
   PubMed Web of Science ®Google Scholar
• NicolinVNarducciPBareggiRRole of neridronate on MCF-7 estrogen dependent breast cancer model of bone metastasis: a preliminary studyInvest New Drugs201129118919119798468
   PubMed Web of Science ®Google Scholar
• ClericoAPaianoMSuraciSMarucciGZambranoAVarrassoGIntravenous neridronate in children affected by malignancies: preliminary results; Pediatric Blood & Cancer39th Annual Conference of the International Society of Paediatric Oncology SIOP 2007Mumbai, India31 October–3 November 2007 SIOP Abstracts49Supplement 6 pages 5131102007
   Google Scholar